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National Trends in Nonstatin Use and Expenditures Among the US
Adult Population From 2002 to 2013: Insights From Medical
Expenditure Panel Survey
Joseph A. Salami, MD, MPH;* Haider J. Warraich, MD;* Javier Valero-Elizondo, MD, MPH; Erica S. Spatz, MD, MHS; Nihar R. Desai, MD,
MPH; Jamal S. Rana, MD, PhD; Salim S. Virani, MD, PhD; Ron Blankstein, MD; Amit Khera, MD; Michael J. Blaha, MD, MPH;
Roger S. Blumenthal, MD; Barry T. Katzen, MD; Donald Lloyd-Jones, MD, ScM; Harlan M. Krumholz, MD, SM; Khurram Nasir, MD, MPH
Background-—Evidence supporting nonstatin lipid-lowering therapy in atherosclerotic cardiovascular disease risk reduction is
variable. We aim to examine nonstatin utilization and expenditures in the United States between 2002 and 2013.
Methods and Results-—We used the Medical Expenditure Panel Survey database to estimate national trends in nonstatin use and
cost (total and out-of-pocket, adjusted to 2013 US dollars using a gross domestic product deflator) among adults 40 years or
older. Nonstatin users increased from 3 million (2.5%) in 2002-2003 (20.1 million prescriptions) to 8 million (5.6%) in 2012-2013
(45.8 million prescriptions). Among adults with atherosclerotic cardiovascular disease, nonstatin use increased from 7.5% in 2002-
2003 to 13.9% in 2012-2013 after peaking at 20.3% in 2006-2007. In 2012-2013, 15.9% of high-intensity statin users also used
nonstatins, versus 9.7% of low/moderate-intensity users and 3.6% of statin nonusers. Nonstatin use was significantly lower among
women (odds ratio 0.80; 95% confidence interval 0.75-0.86), racial/ethnic minorities (odds ratio 0.41; 95% confidence interval
0.36-0.47), and the uninsured (odds ratio 0.47; 95% confidence interval 0.40-0.56). Total nonstatin expenditures increased from
$1.7 billion (out-of-pocket cost, $0.7 billion) in 2002-2003 to $7.9 billion (out-of-pocket cost $1.6 billion) in 2012-2013, as per-
user nonstatin expenditure increased from $550 to $992. Nonstatin expenditure as a proportion of all lipid-lowering therapy
expenditure increased 4-fold from 8% to 32%.
Conclusions-—Between 2002 and 2013, nonstatin use increased by 124%, resulting in a 364% increase in nonstatin-associated
expenditures. ( J Am Heart Assoc. 2018;7:e007132. DOI: 10.1161/JAHA.117.007132.)
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A lthough statins remain the cornerstone of atheroscle-rotic cardiovascular disease (ASCVD) risk reduction,
there has been considerable interest in nonstatin cholesterol-
lowering medications, as adjunct lipid-lowering therapy (LLT),
in combination with statins or as substitutes in statin-
intolerant patients.1 These agents include fibrates (eg,
gemfibrozil), cholesterol absorption inhibitors (ezetimibe), bile
acid sequestrants (eg, colesevelam), cholesterol-lowering
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combinations (ezetimibe+simvastatin), niacin, and x-3 fatty
acids, with PCSK9 inhibitors the most recent addition to this
category.2
The clinical utility and application of nonstatin LLT for
ASCVD risk reduction, however, remain uncertain. This was
highlighted in the 2013 American Heart Association/Ameri-
can College of Cardiology guidelines for cholesterol manage-
ment, which reflected weak evidence for nonstatin
medications observed by several randomized controlled trials,
including ENHANCE (Ezetimibe and Simvastatin in Hyperch-
olesterolemia Enhances Atherosclerosis Regression),3 AIM-
HIGH (Atherothrombosis Intervention in Metabolic Syndrome
with Low HDL/High Triglycerides: Impact on Global Health
Outcome),4 and ACCORD (Action to Control Cardiovascular
Risk in Diabetes).5 However, a recently published American
College of Cardiology expert consensus document, written
after the publication of IMPROVE-IT (Improved Reduction of
Outcomes: Vytorin Efficacy International Trial)6 and FOURIER
(Further Cardiovascular Outcomes Research With PCK9
Inhibition in Subjects With Elevated Risk),7 provides clinical
guidance for nonstatin use but noted that the evidence base
for the various agents is heterogeneous given that several
medications in this class such as niacin, fibrates, and bile acid
sequestrants lack strong contemporary evidence.8 However,
to date, time trends in the utilization of nonstatin use and
associated expenditure at a national level remain unknown.
Therefore, we analyzed the 2002-2013 MEPS (Medical
Expenditures Panel Survey) database to quantify time trends
in utilization, cost, and patient cost shares associated with
nonstatin LLT in a representative US adult population aged
40 years and older.
Methods
Study Design and Population
The MEPS data sets and codebooks used for this study are
available to the public on the AHRQ (Agency for Healthcare
Research and Quality) website.9 We performed a 12-year
retrospective, longitudinal cohort study of US adults 40 years
and older using the 2002-2013 MEPS database. MEPS is an
AHRQ-sponsored national survey of individuals and families,
medical providers, and employers for medical conditions,
healthcare resource use, expenditures, and sources of pay-
ment. It has an overlapping panel design, with each panel
comprised of randomly sampled, noninstitutionalized US civil-
ians. Participants are interviewed over the telephone every
6 months over a period of 30 months, and their responses are
reported annually to provide nationally representative esti-
mates of sociodemographic characteristics, medical condi-
tions, healthcare use, and costs.10 Additional information is
obtained from physicians, hospitals, and pharmacies to
supplement healthcare utilization and cost data gathered from
interviewees. After data collection, AHRQ researchers assign
person weights and variance estimation strata to reflect survey
nonresponse and population totals from the participants
surveyed.9 Because MEPS data are publicly available, contain-
ing deidentified information for participants who provided
written consents to be contacted for interviews and for their
physicians and pharmacies to be contacted too, this current
study was exempted from the Baptist Health South Florida
Institutional Review Board approval, per the US Department of
Health and Human Service guidelines.
We merged the full-year consolidated medical conditions
and prescribed medicines files of the MEPS Household
Components for each year from 2002 to 2013 to create
annual files with sociodemographic characteristics, medical
conditions, medication use, and expenditures and then
created 2-year cycles with adjusted final person weight to
reflect the average annual population size, medication utiliza-
tion, and expenditure of the 2 years in each cycle. Individuals
included in our analysis were ≥40 years of age at the time of
survey, had a body mass index ≥18.5 kg/m2 (underweight
individuals generally represent a sicker population),11 and
with a survey person weight >0 in order to be representative
of the national population at the time of survey (Figure S1).
Our study population was stratified into 2 groups by
ASCVD risk: (1) participants with known ASCVD, eg, coronary
heart disease, stroke, and/or peripheral arterial disease and
(2) participants without known ASCVD. Participants were
classified into these groups if they had an International
Classification of Disease Ninth Edition Clinical Modification
(ICD-9 CM) diagnosis of the condition and/or self-reported
history of the diagnosis (Table S1).
Clinical Perspective
What Is New?
• Use of nonstatin lipid-lowering therapies is frequent among
US adults, doubling between 2002 and 2013, with 1 in 7
atherosclerotic cardiovascular disease patients using them
in 2012-2013.
• Our study found that in current clinical practice, nonstatins
are primarily used as an adjunct to statins rather than in
statin-intolerant patients.
• Overall cost associated with nonstatin lipid-lowering thera-
pies increased almost 5-fold from $1.7 billion in 2002-2003
to $7.9 billion in 2012-2013.
What Are the Clinical Implications?
• These findings should guide pragmatic discussions among
stakeholders for appropriate use of current and upcoming
nonstatin lipid-lowering therapies, especially for atheroscle-
rotic cardiovascular disease risk management.
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Nonstatin Utilization and Expenditures
MEPS-prescribed medicine data collection and collation, the
linking to Multum drug codes, and the validity of the data have
been described elsewhere.12 In this study we defined
nonstatin as any lipid-lowering drug other than a HMG-CoA
reductase inhibitor (statin); thus, the Multum codes 241 (fibric
acid derivatives), 252 (bile acid sequestrants), 316 (choles-
terol absorption inhibitors), and 317 (antihyperlipidemic
combinations) were classified as nonstatin lipid-lowering
drugs. Prescription niacin and x-3 fatty acids were also
classified as nonstatins using the variable specifying the
medication name provided in the prescribed medicine files.
For each drug prescribed, the exact dollar amount paid was
reported, as well as the source of payment (out-of-pocket or
specific insurance coverage). Using these variables, we calcu-
lated drug-specific expenditures (overall expenditure and out-
of-pocket). All expenditures were adjusted to constant 2013US
dollars using the gross domestic product deflator.
Covariates
In our analyses, we considered age, sex, race/ethnicity, family
income, modifiable cardiovascular disease risk factors, and
Charlson comorbidity index as potential factors that affect the
time trends in nonstatin utilization and expenditure, and we
treated them as covariates in our analyses. Participants’ ages
as of December 31 of the survey year were categorized into 40
to 64, 65 to 74, & ≥75 years. We had 5 categories of race and
ethnicity: “non-Hispanic white,” “non-Hispanic black,” “His-
panic,” “Asian,” and “Other” (American Indian, Alaska Native,
and those who reported multiple race); Five categories of
family income level as a proportion of the federal poverty level
(FPL): poor (<100% of FPL), near-poor (100% to <125% of FPL),
low income (125% to <200% of FPL), middle income (200% to
<400% of FPL), and high income (≥400% of FPL). We estimated
participant’s comorbidity burden using the Grouped Charlson
Comorbidity Index, which has been described extensively
elsewhere.13,14 For our analysis, however, we modified the
Grouped Charlson Comorbidity Index by excluding acute
myocardial infarction, congestive heart failure, peripheral
vascular disease, cerebrovascular disease, and diabetes
mellitus to avoid collinearity in our regression analyses. There
were 3 categories for Grouped Charlson Comorbidity Index: 0,
no comorbidity; 1, 1 chronic condition; and 2, two or more
chronic conditions present other than CVD and/or diabetes
mellitus. Hypertension, diabetes mellitus, and hyperlipidemia,
which we also treated as covariates, were determined using
ICD-9 CM diagnoses (Table S1) or self-report.
Statistical Analysis
All analyses were conducted using Stata version 14
(StataCorp, College Station, TX). After pooling 2-year data
together to form cycles (a total of 6 cycles for the 12-year
study period), we halved the final person weight to adjust it
for the 2-year cycles.15 Using the adjusted weight and
variance estimations (person sampling units and stratum), we
accounted for the complex sampling design of MEPS in all
analyses to estimate annual nationally representative rates,
totals, and means for our study population. We used the svy:
proportion command in Stata to estimate population-level
percentage nonstatin use; svy: total to estimate total numbers
of persons reporting nonstatin use, total prescriptions, and
total expenditures (in 2013 USD); and the svy: mean to
estimate the average expenditures on any nonstatin (in 2013
USD). When stratified by study cycle, the outputs of these
commands are estimates of the time trends of nonstatin use
and expenditure over the study period. Using 3 different
models of weighted logistic regression, we determined which
factors are likely predictors of nonstatin use (versus nonuse):
first, the univariate logistic regression; second, model 1,
consisting of each univariate predictor adjusted for age, sex,
and race/ethnicity; and model 2, which consisted of all the
predictor variables. We reported odd ratios of nonstatin use
using 2002-2003 as the reference cycle. In all analyses 95%
confidence intervals (CIs) were reported, and 2-sided P<0.05
was considered statistically significant.
Results
Between 2002 and 2013, 157 719 MEPS participants were
eligible for the study (mean age [SD]: 57.7 [39.9] years; 52.1%
female) (Figure S1). The characteristics of the study popula-
tion are shown in Table 1. Significant increases were noted in
subjects between 65 and 74 years of age, patients enrolled in
federal insurance programs such as Medicaid and Medicare,
patients who were “poor” or “near poor,” and patients with
multiple noncardiovascular comorbidities. A 12-year average
of 6.1% (95% CI 5.9% to 6.4%) of adults aged 40 years or older
reported nonstatin use; 13.7% of all nonstatin users reported
only 1 prescription, 10.9% had 2 prescriptions, and 75.4% of
the study population had 3 or more prescriptions. The
characteristics of those taking nonstatins versus those not
taking nonstatins over the 12-year period are detailed in
Tables S2 and S3, respectively. Throughout the study period,
the majority of nonstatin users were non-Hispanic, most
commonly white and male, between the ages of 40 and
64 years, and usually had health insurance. Hyperlipidemia
was the most prevalent ASCVD risk factor among nonstatin
users (91.7% in 2003-2003, 94.7% in 2012-2013).
Trends in Non-Statin Utilization
Non-statins use over the 12-year study period is shown in
Figure 1. The number of adults in the general population who
DOI: 10.1161/JAHA.117.007132 Journal of the American Heart Association 3
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Table 1. Characteristics of US Adults Aged 40 and Above Over a 12-Year Period, MEPS 2002-2013
Cycle 2002-2003 2004-2005 2006-2007 2008-2009 2010-2011 2012-2013
P Value*N (Millions) 121 126 129 133 136 141
Characteristics
Age, y
Mean age (SE) 56.9 (0.2) 57.1 (0.2) 57.4 (0.2) 57.7 (0.2) 58.1 (0.2) 58.5 (0.2) <0.001†
Age category, y %
40 to 64 73.0 73.0 72.9 72.6 71.6 69.9 <0.001†
65 to 74 14.6 14.4 14.3 14.8 15.9 17.4
75 or older 12.4 12.6 12.8 12.6 12.5 12.7
Sex, %
Male 47.6 47.9 48.1 47.9 48.1 47.8 0.849
Female 52.4 52.1 51.9 52.1 51.9 52.2
Race/ethnicity, %
Non-Hispanic white 75.8 74.7 73.9 73.4 72.5 71.1 0.008†
Non-Hispanic black 10.3 10.2 10.5 10.3 10.6 10.8
Asian 3.6 3.7 4.1 4.0 4.4 4.9
Hispanic 8.6 9.3 9.9 10.4 10.9 11.4
Other 1.7 2.1 1.7 1.8 1.7 1.8
Insurance status, %
Uninsured 9.1 9.7 10.3 11.1 10.4 11.2 <0.001†
Private only 57.2 56.0 55.7 54.0 53.7 51.3
Medicaid 3.3 3.7 3.2 3.5 5.6 7.6
Medicare 12.6 12.7 14.1 15.6 22.0 29.7
Other (public/private) 18.0 17.9 16.8 15.7 8.2 0.3
Family income level, %
Poor (<100% of FPL) 8.9 8.9 8.7 9.3 10.1 10.3 0.007†
Near poor (100% to 124% of FPL) 3.8 3.8 4.1 4.2 4.1 4.3
Low income (125% to 199% of FPL) 12.3 12.6 12.0 12.6 12.8 12.8
Middle income (200% to 399% of FPL) 28.6 29.4 29.1 29.1 29.0 28.6
High income (≥400% of FPL) 46.3 45.2 46.1 44.9 44.0 43.9
Region, %
Northeast 22.0 20.8 21.5 19.4 19.7 18.7 0.454
Midwest 23.4 24.4 22.3 23.3 23.1 23.5
South 37.2 34.7 36.8 37.2 37.5 37.7
West 17.5 20.1 19.5 20.2 19.8 20.2
GCCI‡, %
0 86.7 86.2 85.4 82.1 81.8 83.6 <0.001†
1 8.9 9.4 9.9 11.1 11.4 11.1
≥2 4.4 4.4 4.8 6.9 6.8 5.4
History of, %
CHD 9.3 9.3 9.4 12.6 12.2 12.0 <0.001†
Stroke 4.6 4.4 4.7 5.9 5.8 5.9 <0.001†
PAD 0.3 0.3 0.2 0.1 0.1 0.1 <0.001†
Continued
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reported using non-statins increased from 3 million (2.5%) in
2002-2003 to 10.6 million (8.0%) in 2008-2009, and then
declined to 8 million (5.6%) in 2012-2013, representing a 162%
increase in non-statin users between 2002 and 2013. Non-
statin prescriptions increased from 20.1 to 45.8 million (64.9%
increase), peaking at 62.2 million in 2008-2009. The publica-
tion dates of clinical trials results relevant to non-statin are also
shown in Figure 1. The pattern of non-statin use and its
variation across participants’ characteristics over the 12-year
period are detailed in Table 2, showing increases in non-statin
use amongst all reported groups and subgroups. Non-statin use
was consistently lower among adults aged 40 to 64 years,
females, the uninsured, and consistently higher among non-
Hispanic whites. A similar pattern was observed among adults
with ASCVD, whose non-statin use increased from 7.5% in
2002-2003, to 13.9% in 2012-2013, after peaking at 20.3% in
2006-2007. The patterns of use among those with ASCVD and
those without ASCVD are detailed in Tables S4 and S5.
Fibrates top the most used nonstatins in 2002-2003,
before the introduction of cholesterol absorption inhibitors.
After their introduction, cholesterol absorption inhibitors
became the most widely used in 2004-2005, peaked in
2006-2007, and then declined to second most used
nonstatins from 2010-2011 and onward, behind fibrates
(Figure S2). Fibrate use did not change significantly over
the 12-year period. Similar patterns were observed among
those with and those without ASCVD.
Throughout the study period, the rate of nonstatin use
was highest among adults already using high-intensity
statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg
Table 1. Continued
Cycle 2002-2003 2004-2005 2006-2007 2008-2009 2010-2011 2012-2013
P Value*N (Millions) 121 126 129 133 136 141
Diabetes mellitus 10.7 12.1 13.5 14.8 15.4 15.5 <0.001†
Dyslipidemia 45.1 43.2 40.0 46.6 46.0 47.1 <0.001†
CHD indicates coronary heart disease; FPL, federal poverty level; GCCI, Grouped Charlson Comorbidity Index; MEPS, Medical Expenditure Panel Survey; PAD, peripheral arterial disease; SE,
standard error.
*P-values for year effect on population characteristics were computed using linear regression for mean age and Pearson chi-squared test for proportions.
†Statistically sigificant.
‡GCCI was modified for this study by excluding any cardiovascular disease or diabetes mellitus from the comorbidity index computation.
Trial Results Published:
ENHANCE, April 2008
ACCORD, March 2010
AIM-HIGH, December 2011
0
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N
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Adults with ASCVD
Adults without ASCVD
Figure 1. Trends in nonstatin utilization among the general population, adults with ASCVD, and those
without ASCVD between 2002 and 2013. ASCVD indicates atherosclerotic cardiovascular diseases;
ENHANCE, Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression; AIM-
HIGH, Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on
Global Health Outcome; ACCORD, Action to Control Cardiovascular Risk in Diabetes.
DOI: 10.1161/JAHA.117.007132 Journal of the American Heart Association 5
Nonstatin Use and Expenditure Salami et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
 by guest on February 5, 2018
http://jaha.ahajournals.org/
D
ow
nloaded from
 
daily), followed by those on low/moderate-intensity statin
(Figure 2). A similar trend was observed among those without
ASCVD; in these participants, significantly higher use of
nonstatins among patients on high-intensity statins was only
noted between 2006 and 2011.
Predictors of Nonstatin Use
The likelihood of any nonstatin use in the study population
increased from 2002-2003 to 2008-2009, and then declined
over the following 2 cycles (Table 3). In the multivariable-
Table 2. Variation in Trends in Nonstatin Use Among US Adults Aged ≥40 Years, MEPS 2002-2013
Cycle 2002-2003 2004-2005 2006-2007 2008-2009 2010-2011 2012-2013
N (Millions) 121 126 129 133 136 141
Age category y
40 to 64 2.1 (1.8-2.4) 4.5 (4.0-4.9) 6.3 (5.7-6.8) 6.2 (5.7-6.7) 5.2 (4.8-5.7) 4.2 (3.7-4.7)
65 to 74 4.0 (3.3-4.9) 9.6 (8.4-11.0) 12.9 (11.5-14.3) 13.2 (11.5-15.0) 12.2 (10.9-13.7) 9.8 (8.6-11.2)
75 or older 3.0 (2.4-3.7) 7.9 (6.8-9.1) 11.0 (9.6-12.5) 12.0 (10.5-13.8) 10.0 (8.6-11.6) 7.9 (6.5-9.5)
Sex
Male 3.2 (2.8-3.6) 6.3 (5.7-7.0) 9.0 (8.2-9.7) 9.1 (8.5-9.8) 8.1 (7.4-8.9) 6.9 (6.2-7.7)
Female 1.9 (1.6-2.3) 5.0 (4.5-5.4) 6.7 (6.2-7.3) 6.9 (6.2-7.6) 5.9 (5.4-6.4) 4.5 (4.0-5.0)
Race/ethnicity
Non-Hispanic white 2.8 (2.5-3.1) 6.3 (5.8-6.9) 8.6 (8.0-9.2) 8.9 (8.3-9.6) 7.8 (7.2-8.4) 6.4 (5.8-7.1)
Non-Hispanic black 1.0 (0.7-1.4) 2.6 (2.1-3.4) 4.9 (4.0-6.0) 3.7 (3.1-4.4) 3.4 (2.8-4.2) 2.6 (2.1-3.3)
Asian 2.6 (1.5-4.6) 4.0 (2.6-6.1) 4.4 (3.2-5.9) 6.5 (4.6-9.2) 5.1 (3.9-6.7) 4.5 (3.3-6.1)
Hispanic 1.6 (1.2-2.2) 4.0 (3.3-4.8) 6.1 (5.2-7.1) 5.7 (4.8-6.7) 5.2 (4.4-6.0) 4.3 (3.7-4.9)
Other 2.7 (1.1-6.1) 5.0 (3.1-8.0) 8.9 (5.9-13.4) 10.1 (6.7-14.9) 8.3 (5.5-12.3) 5.6 (3.4-9.2)
Insurance status
Uninsured 1.1 (0.7-1.8) 2.1 (1.4-3.2) 2.3 (1.7-3.1) 2.6 (2.0-3.4) 2.2 (1.7-2.9) 1.8 (1.3-2.5)
Private only 2.1 (1.8-2.5) 4.5 (3.9-5.1) 6.5 (5.9-7.1) 6.5 (5.9-7.2) 5.2 (4.7-5.8) 4.4 (3.8-5.0)
Medicaid 2.6 (1.8-3.6) 4.8 (3.6-6.5) 6.6 (4.8-9.1) 6.3 (4.6-8.5) 8.0 (6.6-9.7) 6.6 (5.2-8.4)
Medicare 3.3 (2.7-4.0) 8.0 (6.7-9.4) 10.0 (8.8-11.4) 10.5 (9.2-11.9) 10.6 (9.7-11.6) 9.1 (8.1-10.2)
Other (public/private) 4.0 (3.3-4.8) 9.6 (8.6-10.8) 14.0 (12.7-15.5) 14.5 (13.1-16.1) 13.7 (12.1-15.6) 6.0 (1.2-25.0)
Family income level
Poor (<100% of FPL) 2.5 (1.9-3.2) 5.1 (4.3-6.0) 7.5 (6.3-8.9) 7.2 (6.0-8.8) 7.4 (6.4-8.6) 5.1 (4.1-6.4)
Near poor (100% to 124% of FPL) 2.4 (1.6-3.5) 5.2 (3.9-6.9) 7.8 (6.3-9.6) 8.6 (6.8-11.0) 6.9 (5.3-8.9) 6.4 (4.9-8.2)
Low income (125% to 199% of FPL) 2.3 (1.8-3.1) 4.7 (4.0-5.6) 7.3 (6.2-8.4) 7.5 (6.4-8.8) 6.8 (5.8-7.9) 5.5 (4.5-6.7)
Middle income (200% to 399% of FPL) 2.7 (2.3-3.2) 5.5 (4.8-6.3) 7.6 (6.9-8.3) 7.8 (7.0-8.6) 6.8 (6.0-7.6) 5.4 (4.8-6.1)
High income (≥400% of FPL) 2.4 (2.0-2.8) 6.1 (5.5-6.8) 8.2 (7.5-8.9) 8.3 (7.5-9.1) 7.0 (6.2-7.8) 5.9 (5.1-6.7)
Region
Northeast 2.5 (1.8-3.4) 5.4 (4.5-6.6) 7.8 (6.6-9.2) 7.3 (6.1-8.6) 7.2 (6.0-8.6) 5.3 (4.2-6.8)
Midwest 2.4 (1.9-3.0) 5.8 (5.0-6.8) 7.6 (6.7-8.7) 8.8 (7.7-10.1) 7.1 (6.3-8.0) 6.1 (5.1-7.3)
South 3.0 (2.5-3.5) 6.4 (5.8-7.2) 9.0 (8.2-9.8) 8.8 (7.9-9.8) 7.6 (6.8-8.5) 6.1 (5.3-7.0)
West 1.9 (1.5-2.4) 4.2 (3.5-5.2) 6.1 (5.4-6.9) 6.3 (5.5-7.4) 5.4 (4.7-6.3) 4.7 (4.0-5.4)
GCCI†
1 2.4 (2.1-2.7) 5.3 (4.8-5.7) 7.2 (6.7-7.8) 7.3 (6.7-7.8) 6.2 (5.7-6.7) 5.2 (4.7-5.7)
2 2.9 (2.2-3.9) 6.9 (5.8-8.2) 10.1 (8.6-11.8) 10.6 (9.1-12.2) 9.8 (8.4-11.4) 7.7 (6.5-9.1)
3 3.9 (2.6-5.7) 10.2 (8.2-12.5) 13.1 (10.9-15.7) 12.0 (9.9-14.5) 11.6 (9.4-14.2) 8.4 (6.5-10.8)
FPL indicates federal poverty level; GCCI, Grouped Charlson Comorbidity Index; MEPS, Medical Expenditure Panel Survey.
†GCCI was modified for this study by excluding any cardiovascular disease or diabetes mellitus from the comorbidity index computation.
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Figure 2. Trends in utilization of nonstatins by statin intensity among the general population (A),
adults with ASCVD (B), and those without ASCVD (C) between 2002 and 2013. ASCVD indicates
atherosclerotic cardiovascular diseases.
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Table 3. Predictors of Nonstatin Use Among US Adults Aged 40 Years and Older, MEPS 2002-2013
Odds Ratio (95% CI)
Univariate Model 1 Model 2
Cycle
2002-2003 1 (Reference) 1 (Reference) 1 (Reference)
2004-2005 2.33 (2.06-2.62) 2.34 (2.08-2.64) 2.27 (2.01-2.56)
2006-2007 3.30 (2.89-3.77) 2.34 (2.93-3.80) 3.29 (2.89-3.75)
2008-2009 3.37 (2.95-3.86) 3.42 (2.99-3.91) 3.08 (2.69-3.53)
2010-2011 2.91 (2.54-3.33) 2.94 (2.57-3.35) 2.55 (2.21-2.94)
2012-2013 2.33 (2.01-2.70) 2.34 (2.02-2.74) 2.02 (1.75-2.34)
Age, y
40 to 64 1 (Reference) 1 (Reference) 1 (Reference)
65 to 74 2.3 (2.13-2.51) 2.30 (2.12-2.50) 1.09 (0.95-1.24)
75 and above 1.90 (1.75-2.08) 1.92 (1.76-2.10) 0.83 (0.72-0.96)
Sex
Male 1 (Reference) 1 (Reference) 1 (Reference)
Female 0.71 (0.66-0.75) 0.68 (0.64-0.72) 0.80 (0.75-0.86)
Race/ethnicity
Non-Hispanic white 1 (Reference) 1 (Reference) 1 (Reference)
Non-Hispanic black 0.43 (0.38-0.49) 0.46 (0.41-0.52) 0.41 (0.36-0.47)
Hispanic 0.65 (0.59-0.72) 1.05 (0.84-1.33) 0.83 (0.74-0.92)
Asian 0.65 (0.56-0.77) 0.70 (0.59-0.82) 0.84 (0.71-1.00)
Family income level
Poor (<100% of FPL) 1 (Reference) 1 (Reference) 1 (Reference)
Near poor (100% to 124% of FPL) 1.08 (0.94-1.25) 0.95 (0.82-1.09) 0.96 (0.83-1.12)
Low income (125% to 199% of FPL) 0.98 (0.88-1.09) 0.86 (0.77-0.96) 0.94 (0.84-1.06)
Middle income (200% to 399% of FPL) 1.02 (0.93-1.13) 0.96 (0.87-1.06) 1.08 (0.97-1.21)
High income (≥400% of FPL) 1.09 (0.99-1.19) 1.04 (0.94-1.15) 1.21 (1.07-1.36)
Health insurance
Uninsured 1 (Reference) 1 (Reference) 1 (Reference)
Any public (Medicare/Medicaid) 2.44 (2.09-2.85 2.33 (1.99-2.72) 2.13 (1.80-2.52)
Private only 4.88 (4.20-5.67) 4.70 (3.98-5.54) 2.89 (2.38-3.52)
Education
<High school 1 (Reference) 1 (Reference) 1 (Reference)
High school/GED equivalent 1.13 (1.00-1.27) 1.17 (1.03-1.32) 1.21 (1.06-1.39)
Some college or higher 1.01 (0.90-1.13) 1.09 (0.96-1.23) 1.15 (1.01-1.32)
Region
Northeast 1 (Reference) 1 (Reference) 1 (Reference)
Midwest 1.07 (0.94-1.22) 1.06 (0.93-1.21) 1.07 (0.94-1.22)
South 1.17 (1.03-1.32) 1.19 (1.05-1.34) 1.25 (1.10-1.42)
West 0.81 (0.71-0.92) 0.85 (0.74-0.97) 0.88 (0.76-1.01)
History of CHD 4.40 (4.09-4.74) 3.78 (3.48-4.10) 2.49 (2.27-2.72)
History of stroke 2.15 (1.95-2.37) 1.71 (1.53-1.90) 1.04 (0.92-1.17)
History of PAD 4.75 (3.15-7.15) 3.89 (2.57-5.88) 2.04 (1.34-3.09)
Continued
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adjusted Model 2, compared with those aged 40 to 64 years,
adults aged 75 years and above were less likely to report non-
statin use, with OR 0.83 (95% CI: 0.72-0.96), but those aged
65 to 74 years were not statistically significantly different in
their likelihood of non-statin use. Females versus males (OR:
0.80; 95% CI: 0.75-0.86), ethnic minorities (versus non-
Hispanic whites) including non-Hispanic blacks (OR: 0.41; 95%
CI: 0.36-0.47), and Hispanics (OR: 0.83; 95% CI: 0.74-0.92),
as well as uninsured versus public insurance (OR: 0.47; 95%
CI: 0.40-0.56) were significantly less likely to report non-
statin use in the 12-year period. Coronary heart disease,
peripheral arterial disease, and diabetes mellitus were signif-
icant predictors of non-statin use, whereas stroke was not
associated with increased non-statin use in the multivariate
analysis. Predictors of non-statin use among adults aged
40 years and above with and without ASCVD are shown in
Tables S6 and S7. Comorbidity index and other factors were
more important predictors among patients without ASCVD
than among those with ASCVD.
Trends in Non-Statin Expenditure
The annual total expenditures on non-statins was increased
from $1.7 billion in 2002-2003 to $9.4 billion in 2008-2009,
before declining to $7.9 billion in 2012-2013 (Figure 3). Of
these amounts, out-of-pocket costs accounted for 41% of
total costs ($697 million) in 2002-2003 and 20% ($1.6 billion)
in 2012-2013. Among those with ASCVD, total expenditures
on nonstatins increased from $616 million in 2002-2003 to
$3.9 billion in 2010-2011, before trending down to $3.4 bil-
lion in 2012-2013. Beginning in 2004-2005, cholesterol
absorption inhibitors were together responsible for the
highest expenditures among the adult population aged
40 years and above and among those with ASCVD (Figure 4).
Expenditures on these drugs peaked in 2008-2009, and
subsequent reductions were largely driven by reduced
expenditures in patients without ASCVD. Over the study
period, the per-user average expenditures on nonstatins in the
US adult population aged 40 years and above increased by
80% from $550 in 2002-2003 to $992 in 2012-2013. Among
those with ASCVD, the per-user average expenditures doubled
from $541 in 2002-2003 to $1104 in 2012-2013 (Figure S3).
Combined expenditures on LLTs, including statins and
nonstatins, peaked in 2008-2009 at $29.8 billion ($9.4 billion
on nonstatin and $20.4 billion on statins) before trending
down to $24.3 billion. Over the study period, the contribution
of nonstatins to the combined LLT expenditures increased
from 8% in 2002-2003 to 32% in 2012-2013 (Figure 5).
Discussion
Our study provides detailed insights into trends and variation
in utilization as well as costs associated with nonstatin LLT
between 2002 and 2013. Nonstatin LLT utilization in the
general US adult population more than doubled from 2.5%
(3.0 million individuals, 20.1 million prescriptions) in 2002-
2003, to 5.6% (8.0 million adults, 46 million prescriptions) in
2012-2013. Nonstatins were mostly used in patients already
on statins rather than in patients not on statins who could
have been statin intolerant. Over the same period, we also
noted a marked increase in nonstatin expenditures from $1.7
to $7.9 billion, contributing 32% of overall LLT costs (statin
and nonstatin) in 2012-2103.
Hitherto, few studies have detailed utilization of nonstatins
at a population-level. Our results are consistent with the
findings of Bittner et al, who found that nonstatin use among
Table 3. Continued
Odds Ratio (95% CI)
Univariate Model 1 Model 2
History of diabetes mellitus 3.66 (3.42-3.92) 3.49 (3.25-3.75) 2.50 (2.30-2.71)
Statin use
No statin use 1 (Reference) 1 (Reference) 1 (Reference)
Low/moderate use 2.70 (2.49-2.92) 2.39 (2.19-2.60) 1.53 (1.39-1.69)
High-intensity use 5.43 (4.90-6.02) 4.67 (4.18-5.21) 2.43 (2.14-2.75)
GCCI*
0 1 (Reference) 1 (Reference) 1 (Reference)
1 1.51 (1.39-1.65) 1.50 (1.38-1.64) 1.13 (1.03-1.24)
≥2 1.92 (1.70-2.16) 1.57 (1.38-1.78) 1.19 (1.05-1.36)
Model 1: age, sex, and race/ethnicity along with the univariate predictor of statin use included in the model. Model 2: all predictor variables were included in this model. CHD indicates
coronary heart disease; FPL, Federal Poverty Level; GCCI, Grouped Charlson Comorbidity Index; GED, General Education Development; MEPS, Medical Expenditure Panel Survey; PAD,
peripheral arterial disease; CI, confidence interval.
*GCCI was modified for this study by excluding any cardiovascular disease or diabetes mellitus from the comorbidity index computation.
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Figure 3. Trends in overall and out-of-pocket expenditure associated with nonstatins among the
general population (A), adults with ASCVD (B), and those without ASCVD (C) between 2002 and 2013.
ASCVD indicates atherosclerotic cardiovascular diseases; USD, US dollars.
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Figure 4. Trends in expenditures on specific classes of nonstatins among the general population (A),
adults with ASCVD (B), and those without ASCVD (C), from MEPS 2002-2013. ASCVD indicates
atherosclerotic cardiovascular diseases; BAS, Bile Acid Sequestrants; CAI, cholesterol absorption
inhibitor; MEPS, Medical Expenditure Panel Survey; USD, US dollars.
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Medicare ASCVD population declined from 17% in 2008 to
12% in 2011.16 A much higher rate of nonstatin use (23%) was
reported from the National Cardiovascular Data Registry
PINNACLE registry; however, this registry is composed of an
older population (mean age 65 years) with much higher rates
of established ASCVD (91%).17 Furthermore, patients in
PINNACLE were receiving specialist cardiovascular care,
which was shown in an analysis of Medicare data to be
associated with higher nonstatin use.16
Our findings contributed significantly to existing knowledge
by providing insights into time trends of nonstatin use within a
US representative adult cohort into nonstatin use in a non-
Medicare population, as well as those without ASCVD (Tables
S3 and S4). Although our study demonstrates that 14% of
ASCVD patients reported nonstatin use in 2012-2013, we
also noted that nearly 1 of 25 individuals without ASCVD
(4.9 million adults) reported nonstatin LLT (Figure 1), with a
utilization rate proportional to increasing intensity of statin
therapy (Figure 2). Our results indicates that nonstatin LLTs
were used predominantly among patients who were tolerant
of statins. Some variation in patterns of nonstatin use were
noted in our multivariable analysis. Patients perceived to be at
higher risk such as males, those with diseases such as
coronary heart disease, diabetes mellitus, dyslipidemia,
patients with multiple noncardiovascular comorbidities and
patients already prescribed statins were more likely to receive
nonstatin prescriptions. Presumably, the use of nonstatins in
these populations reflect prior guidelines to target an LDL
<70 mg/dL in high-risk populations. We also observed that
people with low income, less education, and ethnic minorities
were less likely to receive nonstatins. Whether these
differences are because of prohibitive costs associated with
these drugs or differences in practice patterns remains
unclear and needs to be further studied. However, given that
nonstatins have not been proven to unequivocally improve
cardiovascular outcomes, underutilization in these groups
may not be particularly undesirable.
Another major contribution of our study to existing
knowledge is the insights into the costs associated with
nonstatin use in the US. Over the study period, total gross
domestic product-adjusted costs associated with nonstatins
peaked at more than $9 billion in 2008-2009. The slightly
lower rates of nonstatin LLT use seen since then may have
been due to a series of trials mostly demonstrating no
cardiovascular outcome benefits of nonstatin LLT.3-5 However,
despite weak evidence for clinical improvement from fibrates
and net harm from niacin, in 2012-2013 they accounted for
$2.5 billion and $873 million in annual national expenditure,
respectively. Of the nonstatins analyzed in our study, ezetimibe
is the only one with favorable evidence, showing modest
absolute risk reduction among patients with acute coronary
syndromes in the IMPROVE-IT trial.18 However, we found in our
study that 1.3 million (1.1%) adults without ASCVD reported
cholesterol absorption inhibitors used (6 million prescriptions)
in 2012-2013, resulting in $3.3 billion in annual expendi-
tures, even before the publication of IMPROVE-IT. Within the
context of the lack of evidence supporting favorable outcomes,
the significant national expenditures of almost $17.9 billion
($4.7 billion direct out-of-pocket costs) between 2002 and
2013 on niacin and fenofibrates, highlight the need for
outcome evidence to guide approval and adoption of future
drugs to avoid risk of significant economic waste.19,20
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Figure 5. Comparison of nonstatin vs statin users and expenditures among the general
population, adults with ASCVD and those without ASCVD between 2002 and 2013. ASCVD
indicates atherosclerotic cardiovascular diseases; LLT, lipid-lowering treatment; USD, US dollars.
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There is consensus among medical establishment that the
overarching goal of cholesterol management is to match
intensity of evidence-based treatmentwith degree of underlying
risk.21 Among ASCVD patients who are at the highest risk,
treatment with high-intensity statins is the most optimal choice
for risk reduction. A recent analysis demonstrated that a third of
US patients with ASCVD are not prescribed high-intensity
statins.12 Suboptimal high-intensity statin use thus remains an
important gap that needs to be more aggressively targeted.
However, if further risk reduction is desired in patients with
established ASCVD already receiving high-intensity statins,
nonstatin treatment may be considered with ezetimibe used
first, and then, possibly, evolocumab.21 For patients presenting
with mild-to-moderate statin intolerance, 2 different statins
should be tried before consideration of evidence-based
nonstatin therapies. On the other hand, for patients with severe
intolerance to statin, use of evidence-based nonstatins is
reasonable without a trial of alternate statins.19
Our study has several limitations. First, our results are not
generalizable to adults in nursing homes or the military
because MEPS was conducted among noninstitutionalized
adults. Second, ASCVD was partly based on self-report,
making underestimation of the risk group’s size possible.
Third, we defined nonstatin utilization without regard for
number of prescriptions so that we can estimate expenditures
as accurately as possible. This could overestimate nonstatin
use, especially as our results do not reflect a pattern of
adherence and long-term utilization. Fourth, niacin and x-3,
each considered in this study as a nonstatin LLT have other
uses and, as such, may have resulted in the overestimation of
nonstatin use. On the flip side, since MEPS did not collect
information on over-the-counter acquired medications, includ-
ing these, an underestimation of use is equally possible.
In conclusion, nonstatin LLTs are frequently used among
US adults with and without ASCVD. Although a modest
downtrend was noted in prescriptions, the cost associated
with nonstatin use increased almost 5-fold from $1.7 billion in
2002-2003 to $7.9 billion in 2012-2013, contributing 32% of
combined expenditures on all LLTs.
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Table S1. ICD-9 CM codes of diseases, MEPS 2002-2013 
 
ICD-9 CM 
Code 
Disease description 
  ASCVD 
  Coronary Heart Disease 
410 Acute myocardial infarction 
413 Angina pectoris 
414 Other forms of chronic ischemic heart disease: 
  Cerebrovascular Disease 
433 Pre-cerebral occlusion 
434 Cerebral artery occlusion 
435 Transient cerebral ischemia 
436 Cerebrovascular accident 
437 Other cerebrovascular disease 
  Peripheral Aterial Disease 
440 Atherosclerosis. Examples: 
440.0 Atherosclerosis of aorta 
440.1 Atherosclerosis of renal artery 
440.2 Atherosclerosis of native arteries of extremities 
440.3 Atherosclerosis of bypass graft of extremities 
  Other Conditions 
250 Diabetes Mellitus 
272 Dyslipidemia 
410 Hypertension 
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 Table S2. Characteristics of U.S. Adults Aged 40 and Above Who Used Non-statins Over a 12 Year Period, MEPS 
2002-2013 
Cycle 
2002-
2003 
2004-
2005 
2006-
2007 
2008-
2009 
2010-
2011 
2012-
2013 
p-
value* 
N (Millions) 3.1 7.1 10 10 9.5 8.0   
Characteristics               
Age, years 60.9 (0.5) 62.5 (0.4) 62.5 (0.4) 62.5 (0.4) 63.5 (0.4) 63.6 (0.5) 0.002 
Mean Age (SE)               
Age Category (%)               
40-64 61.7 57.7 58.3 56.5 54.0 52.0   
65-74 23.6 24.7 23.6 24.5 28.0 30.3 0.035 
75 or Older 14.8 17.6 18.0 19.0 18.0 17.7   
Sex (%)               
Male 60.0 54.0 55.2 54.8 56.1 58.7   
Female 40.0 46.0 44.8 45.2 43.9 41.3 0.170 
Race/ethnicity (%)               
Non-Hispanic White 84.6 84.1 81.6 82.2 81.5 80.7   
Non-Hispanic Black 4.3 4.8 6.6 4.8 5.2 5.0   
Asian 3.7 2.7 2.3 3.3 3.2 3.9 0.469 
Hispanic 5.6 6.6 7.7 7.4 8.1 8.6   
Other 1.8 1.9 1.9 2.3 2.0 1.8   
Insurance status (%)               
Uninsured 3.9 3.7 3.0 3.6 3.4 3.6   
Private only 47.8 44.5 46.1 44.4 40.3 39.6   
Medicaid 3.3 3.2 2.7 2.8 6.5 8.9 <0.001 
Medicare 16.5 18.0 18.0 20.6 33.7 47.6   
Other (Public/Private) 28.5 30.6 30.2 28.7 16.2 0.4   
Family income level (%)               
Poor (<100% of FPL) 8.8 8.1 8.4 8.5 10.8 9.4   
Near Poor (100-124% of FPL) 3.7 3.5 4.1 4.5 4.0 4.8   
Low Income (125-199% of FPL) 11.6 10.6 11.1 11.9 12.5 12.5 0.691 
Middle Income (200-399% of 
FPL) 
31.4 28.7 28.2 28.3 28.4 27.5   
High Income (>=400% of FPL) 44.6 49.1 48.2 46.8 44.3 45.8   
Region (%)               
Northeast 19.6 18.8 19.4 17.3 19.5 17.5   
Midwest 21.8 23.6 21.5 24.6 22.7 23.6   
South 42.6 41.1 41.6 40.4 40.4 40.3 0.982 
West 16.1 16.5 17.5 17.8 17.5 18.6   
GCCI** (%)               
0 82.8 80.6 79.2 75.0 72.6 76.9   
1 10.5 11.5 12.8 14.7 16.0 15.1 <0.001 
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>=2 6.8 7.9 8.0 10.4 11.4 8.0   
History of: (%)               
CHD 32.9 28.0 28.1 32.1 35.1 34.0 0.007 
Stroke 8.6 9.6 9.2 10.4 10.3 11.3 0.578 
PAD 1.8 1.3 0.6 0.5 0.3 0.4 0.091 
Diabetes 33.4 30.7 31.9 35.2 36.2 36.6 0.066 
Dyslipidemia 91.7 93.3 94.4 94.6 95.9 94.7 0.036 
Abbreviations: CHD, Coronary Heart Disease; GCCI, Grouped Charlson Comorbidity Index; MEPS, Medical Expenditure 
Panel Survey; PAD, Peripheral Arterial Disease; SE, Standard Error 
 
* p-value for year effect on population characteristics were computed using linear regression for mean age and Pearson Chi-
squared test for proportions 
**GCCI was modified for this study by excluding any cardiovascular disease or diabetes from the comorbidity index 
computation 
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 Table S3. Characteristics of U.S. Adults Aged 40 and Above Who Did Not Use Non-statins Over a 12 Year Period, MEPS 
2002-2013 
Cycle 
2002-
2003 
2004-
2005 
2006-
2007 
2008-
2009 
2010-
2011 
2012-
2013 
p-
value* 
N (Millions)               
Characteristics               
Age, years               
Mean Age (SE) 
56.8 
(0.2) 56.8 (0.2) 57.0 (0.2) 57.2 (0.2) 57.7 (0.2) 58.2 (0.2) <0.001 
Age Category (%)               
40-64 73.3 73.9 74.1 74.0 73.0 70.9   
65-74 14.3 13.8 13.6 14.0 15.0 16.7 <0.001 
75 or Older 12.4 12.3 12.4 12.0 12.1 12.4   
Sex (%)               
Male 47.3 47.5 47.5 47.3 47.5 47.1   
Female 52.7 52.5 52.5 52.7 52.5 52.9 0.930 
Race/ethnicity (%)               
Non-Hispanic White 75.6 74.1 73.3 72.6 71.8 70.5   
Non-Hispanic Black 10.4 10.6 10.8 10.8 11.0 11.2   
Asian 3.6 3.8 4.2 4.1 4.4 5.0 0.005 
Hispanic 8.7 9.4 10.1 10.7 11.2 11.6   
Other 1.7 2.1 1.7 1.8 1.7 1.8   
Insurance status (%)               
Uninsured 9.2 10.0 10.9 11.8 11.0 11.6   
Private only 57.4 56.7 56.5 54.9 54.7 52.0   
Medicaid 3.3 3.7 3.2 3.6 5.6 7.5 <0.001 
Medicare 12.5 12.4 13.7 15.2 21.2 28.6   
Other (Public/Private) 17.7 17.1 15.7 14.6 7.6 0.3   
Family income level (%)               
Poor (<100% of FPL) 8.9 8.9 8.8 9.4 10.0 10.4   
Near Poor (100-124% of FPL) 3.8 3.9 4.1 4.1 4.1 4.3   
Low Income (125-199% of FPL) 12.4 12.7 12.0 12.7 12.9 12.9 0.009 
Middle Income (200-399% of FPL) 28.5 29.5 29.2 29.1 29.0 28.7   
High Income (>=400% of FPL) 46.4 45.0 46.0 44.7 44.0 43.8   
Region (%)               
Northeast 19.8 19.5 19.4 19.1 18.8 18.5   
Midwest 22.9 22.7 22.1 22.0 22.0 21.7   
South 35.7 35.6 35.8 36.3 36.5 37.1 0.934 
West 21.6 22.2 22.8 22.7 22.7 22.6   
GCCI** (%)               
0 86.8 86.6 85.9 82.7 82.5 84.0   
1 8.9 9.3 9.7 10.7 11.0 10.8 <0.001 
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>=2 4.3 4.1 4.5 6.6 6.5 5.2   
History of: (%)               
CHD 8.7 8.2 7.8 10.9 10.4 10.7 <0.001 
Stroke 4.5 4.1 4.4 5.5 5.4 5.6 <0.001 
PAD 0.2 0.2 0.1 0.1 0.1 0.1 0.002 
Diabetes 10.2 11.0 11.9 13.0 13.8 14.2 <0.001 
Dyslipidemia 43.9 40.2 35.4 42.4 42.3 44.2 <0.001 
Abbreviations: CHD, Coronary Heart Disease; GCCI, Grouped Charlson Comorbidity Index; MEPS, Medical Expenditure Panel 
Survey; PAD, Peripheral Arterial Disease; SE, Standard Error 
 
* p-value for year effect on population characteristics were computed using linear regression for mean age and Pearson Chi-
squared test for proportions 
**GCCI was modified for this study by excluding any cardiovascular disease or diabetes from the comorbidity index 
computation 
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 Table S4. Variation in Trends in Nonstatin Use Among U.S. Adults Aged >=40 Years who Had ASCVD, MEPS 2002-2013 
Cycle 2002-2003 2004-2005 2006-2007 2008-2009 2010-2011 2012-2013 
N (Millions) 15 15 16 22 21 22 
Age Category             
40-64 9.45 (7.58-11.73) 16.15 (13.56-19.14) 22.58 (19.72-25.71) 18.04 (15.91-20.38) 16.97 (14.51-19.74) 13.18 (10.91-15.82) 
65-74 7.29 (5.48-9.64) 17.08 (14.05-20.60) 22.95 (19.49-26.82) 21.84 (18.39-25.73) 21.12 (17.95-24.69) 19.30 (16.04-23.05) 
75 or Older 5.45 (3.96-7.45) 12.57 (10.31-15.24) 16.31 (13.54-19.53) 15.16 (12.76-17.92) 14.75 (12.22-17.70) 10.46 (8.24-13.18) 
Sex              
Male 8.58 (7.17-10.22) 17.54 (15.17-20.19) 23.71 (21.06-26.57) 20.45 (18.38-22.69) 19.90 (17.44-22.61) 16.72 (14.31-19.44) 
Female 6.26 (4.78-8.17) 12.48 (10.44-14.85) 16.81 (14.70-19.15) 15.45 (13.44-17.70) 14.13 (11.98-16.60) 10.68 8.79-12.93) 
Race/ethnicity              
Non-Hispanic White 8.19 (6.87-9.73) 16.35 (14.35-18.57) 22.27 (20.17-24.53) 20.00 (18.17-21.96) 19.20 (17.13-21.46) 15.51 (13.35-17.94) 
Non-Hispanic Black 1.81 (0.85-3.79) 7.00 (4.80-10.09) 13.46 (9.89-18.07) 8.42 (6.08-11.57) 7.80 (5.60-10.76) 5.88 (4.17-8.23) 
Asian 10.53 (4.83-21.47) 9.68 (4.04-21.41)  10.44 (5.09-20.21) 21.57 (13.62-32.42) 15.14 (8.85-24.69) 14.36 (8.76-22.66) 
Hispanic 7.67 (4.61-12.50) 14.70 (10.18-20.75) 12.96 (9.25-17.87) 10.26 (7.55-13.81) 13.05 (9.23-18.13) 11.55 (9.03-14.64) 
Other 5.02 (1.22-18.49) 14.57 (7.27-27.04) 20.27 (9.74-37.45) 20.68 (12.16-32.95) 14.62 (6.79-28.70) 14.88 (8.04-25.88) 
Insurance status              
Uninsured 4.24 (1.65-10.48) 5.75 (2.70-11.80) 11.34 (6.21-19.82) 9.04 (5.51-14.48) 6.59 (4.05-10.54) 7.48 (4.15-13.13) 
Private only 11.29 (8.75-14.44) 18.99 (15.24-23.40) 26.86 (22.80-31.34) 21.24 (18.10-24.76) 18.94 (15.21-23.34) 13.81 (11.07-17.08) 
Medicaid 6.10 (3.44-10.59) 10.96 (6.90-16.97) 13.63 (7.57-23.32) 12.83 (7.75-20.51) 14.28 (10.43-19.26) 14.08 (9.85-19.74) 
Medicare 5.68 (4.22-7.61) 13.47 (10.90-16.53) 15.98 (13.36-18.99) 13.71 (11.56-16.19) 16.92 (14.92-19.12) 14.58 (12.57-16.85) 
Other (Public/Private) 7.16 (5.57-9.15) 15.77 (13.23-8.69) 22.00 (18.94-25.39) 22.98 (19.59-26.75) 21.15 (17.64-25.15) 23.60 (5.76-60.98) 
Family income level              
Poor (<100% of FPL) 6.07 (4.20-8.70) 10.62 (8.32-13.45) 14.32 10.93-18.55) 10.83 (8.50-13.71) 15.80 (13.22-18.79) 11.18 (8.43-14.69) 
Near Poor (100-124% of FPL) 5.99 (3.50-10.09) 11.54 (7.77-16.83) 17.63 (12.87-23.66) 17.06 (12.47-22.89) 11.02 (7.28-16.35) 13.04 (8.69-19.12) 
Low Income (125-199% of 
FPL) 
6.29 (4.22-9.27) 11.00 (8.69-13.83) 19.61 (15.85-24.00) 16.75 (13.44-20.68) 14.65 (11.66-18.24) 10.60 (8.18-13.63) 
Middle Income (200-399% of 
FPL) 
8.86 (7.05-11.07) 14.41 (11.80-17.48) 18.73 (16.07-21.71) 18.44 (15.71-21.52) 16.64 (13.69-20.08) 14.29 (11.56-17.53) 
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High Income (>=400% of 
FPL) 
7.96 (6.16-10.24) 20.42 (16.98-24.36) 24.90 (21.45-28.70) 21.72 (18.70-25.07) 21.08 (17.65-24.97) 17.14 (14.19-20.55) 
Region              
Northeast 6.07 (3.76-9.66) 14.13 (11.44-17.33) 23.16 (18.77-28.22) 18.65 (14.91-23.08) 19.14 (15.18-23.84) 13.70 (9.33-19.67) 
Midwest 6.23 (4.26-9.03) 17.27 (14.08-21.00) 19.04 (15.88-22.65) 22.83 (20.03-25.90) 19.45 (16.00-23.43) 18.52 (14.69-23.08) 
South 10.03 (8.20-12.23) 17.09 (14.17-20.47) 21.27 (18.72-24.06) 16.92 (14.78-19.30) 16.11 (13.71-18.84) 12.34 (10.15-14.91) 
West 5.73 (3.63-8.93) 9.44 (6.82-12.94) 17.64 (13.92-22.11) 14.10 (10.49-18.70) 15.31 (12.07-19.22) 12.57 (10.36-15.17) 
GCCI**              
0 7.65 (6.39-9.13) 15.30 (13.31-7.52) 20.31 (18.32-22.45) 18.46 (16.60-20.47) 17.15 (15.00-19.54) 13.93 (12.05-16.05) 
1 7.25 (4.80-10.82) 14.79 (11.56-8.75) 19.95 (15.91-24.71) 17.44 (14.23-21.19) 17.04 (13.98-20.61) 14.71 (11.60-18.47) 
>=2 6.99 (4.18-11.46) 14.97 (10.85-20.30) 22.72 (16.35-30.65) 16.96 (13.33-21.35) 18.46(14.33-23.46) 13.40 (8.95-19.59) 
Abbreviations: CHD, Coronary Heart Disease; FPL, Federal Poverty Level; GCCI, Grouped Charlson Comorbidity Index; MEPS, Medical Expenditure Panel Survey; PAD, Peripheral 
Arterial Disease; SE, Standard Error 
 
* p-value for year effect on population characteristics were computed using linear regression for mean age and Pearson Chi-squared test for proportions 
**GCCI was modified for this study by excluding any cardiovascular disease or diabetes from the comorbidity index computation 
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Table S5. Variation in Trends in Nonstatin Use Among U.S. Adults Aged >=40 Years Without ASCVD, MEPS 2002-2013 
Cycle 2002-2003 2004-2005 2006-2007 2008-2009 2010-2011 2012-2013 
N (Millions) 106 110 113 112 115 119 
Age Category             
40-64 1.58 (1.32-1.90) 3.59 (3.22-4.01) 5.05 (4.58-5.58) 4.99 (4.47-5.58) 4.09 (3.71-4.50) 3.35 (2.9-13.86) 
65-74 3.04 (2.28-4.04) 7.52 (6.24-9.05) 10.12 (8.74-11.69) 9.71 (8.20-11.46) 9.23 (7.86-10.82) 6.60 (5.42-8.01) 
75 or Older 1.76 (1.21-2.55) 5.58 (4.43-7.02) 8.21 (6.82-9.85) 9.75 (7.77-12.17) 6.60 (5.23-8.29) 6.11 (4.61-8.06) 
Sex              
Male 2.24 (1.88-2.66) 4.57 (3.99-5.23) 6.63 (5.95-7.37) 6.64 (5.95-7.40) 5.54 (4.91-6.25) 4.79 (4.12-5.57) 
Female 1.39 (1.10-1.75) 4.04 (3.65-4.48) 5.45 (4.91-6.05) 5.44 (4.75-6.22) 4.58 (4.09-5.12) 3.50 (3.03-4.05) 
Race/ethnicity              
Non-Hispanic White 1.96 (1.65-2.32) 4.81 (4.36-5.31) 6.53 (5.99-7.11) 6.53 (5.99-7.11) 5.54 (5.04-6.09) 4.62 (4.02-5.29) 
Non-Hispanic Black 0.93 (0.62-1.40) 2.08 (1.51-2.86) 3.72 (2.85-4.85) 3.72 (2.85-4.85) 2.54 (1.91-3.38) 1.98 (1.48-2.63) 
Asian 1.91 (0.91-3.96) 3.60 (2.25-5.73) 4.00 (2.87-5.54) 4.00  (2.87-5.54) 4.14 (3.07-5.58) 3.65 (2.61-5.09) 
Hispanic 1.16 (0.79-1.70) 3.11 (2.50-3.86) 5.39 (4.48-6.47) 5.39 (4.48-6.47) 4.18 (3.53-4.95) 3.26 (2.67-3.99) 
Other 2.27 (0.80-6.26) 3.68 (2.02-6.60) 6.82 (4.12-11.11) 6.82 (4.12-11.11) 7.05 (4.33-11.28) 3.53 (1.63-7.48) 
Insurance status              
Uninsured 0.91 (0.51-1.63) 1.89 (1.22-2.92) 1.73 (1.20-2.50) 2.02 (1.47-2.77) 1.83 (1.30-2.57) 1.38 (0.93-2.04) 
Private only 1.58 (1.28-1.96) 3.64 (3.19-4.15) 5.30 (4.75-5.91) 5.42 (4.80-6.11) 4.19 (3.77-4.67) 3.68 (3.14-4.31) 
Medicaid 1.83 (1.06-3.15) 3.91 (2.68-5.65) 5.30 (3.60-7.74) 4.48 (3.05-6.54) 6.25 (4.77-8.16) 4.19 3.07-5.70) 
Medicare 2.24 (1.66-3.03) 5.75 (4.58-7.18) 7.75 (6.53-9.18) 8.66 (7.15-10.44) 7.51 (6.52-8.63) 6.49 (5.48-7.67) 
Other (Public/Private) 2.85 (2.14-3.77) 7.59 (6.40-8.97) 11.10 (9.74-12.62) 10.50 (9.04-12.16) 10.40 (8.59-12.52) 2.91 (0.40-18.22) 
Family income level (% of FPL)             
Poor (<100%) 1.64 (1.13-2.37) 3.96 (3.22-4.87) 6.05 (4.77-7.63) 6.15 (4.77-7.90) 5.09 (4.04-6.39) 3.33 (2.49-4.44) 
Near Poor (100-124%) 1.46 (0.78-.71) 3.65 (2.44-5.45) 5.07 (3.81-6.72) 5.13 (3.56-7.34) 5.66 (4.05-7.87) 4.30 (3.09-5.95) 
Low Income (125-199% ) 1.43 (0.97-2.10) 3.49 (2.73-4.43) 4.79 (3.86-5.94) 4.93 (3.97-6.11) 4.69 (3.77-5.81) 4.12 (3.18-5.33) 
Middle Income (200-399%) 1.85 (1.48-2.30) 4.16 (3.56-4.86) 5.99 (5.33-6.72) 5.64 (4.91-6.47) 4.89 (4.22-5.65) 3.84 (3.22-4.56) 
High Income (>=400%) 1.88 (1.51-2.33) 4.69 (4.11-5.33) 6.38 (5.73-7.09) 6.53 (5.78-7.37) 5.14 (4.50-5.87) 4.41 (3.72-5.21) 
Region              
Northeast 1.99 (1.27-3.11) 4.36 (3.43-5.53) 5.80 (4.74-7.09) 5.13 (4.02-6.54) 4.96 (3.96-6.19) 3.77 (2.84-4.98) 
Midwest 1.81 (1.36-2.41) 4.15 (3.46-4.96) 5.80 (4.89-6.86) 5.91 (4.77-7.30) 4.75 (4.03-5.59) 3.76 (2.94-4.80) 
South 1.90 (1.53-2.35) 4.76 (4.20-5.38) 6.98 (6.24-7.79) 7.10 (6.10-8.25) 5.93 (5.20-6.74) 4.82 (3.93-5.90) 
West 1.37 (1.02-1.83) 3.64 (2.91-4.55) 4.89 (4.30-5.56) 5.08 (4.33-5.95) 3.93 (3.31-4.65) 3.56 (2.87-4.40) 
GCCI**              
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0 1.73 (1.45-2.05) 4.04 (3.64-4.47) 5.67 (5.21-6.17) 5.49 (4.94-6.09) 4.51 (4.11-4.93) 3.87 (3.39-4.42) 
1 1.88 (1.28-2.77) 5.03 (3.97-6.36) 7.30 (5.93-8.95) 8.23 (6.82-9.91) 7.21 (5.77-8.98) 5.24 (4.07-6.74) 
>=2 2.88 1.60-5.12) 8.58 (6.41-11.39) 10.36 8.24-12.96) 9.82 (7.58-12.63) 8.91 (6.61-11.89) 6.13 (4.29-8.69) 
Abbreviations: CHD, Coronary Heart Disease; FPL, Federal Poverty Level; GCCI, Grouped Charlson Comorbidity Index; MEPS, Medical Expenditure Panel Survey; PAD, 
Peripheral Arterial Disease; SE, Standard Error 
 
* p-value for year effect on population characteristics were computed using linear regression for mean age and Pearson Chi-squared test for proportions 
**GCCI was modified for this study by excluding any cardiovascular disease or diabetes from the comorbidity index computation 
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 Table S6. Predictors of Nonstatin Use Among U.S. Adults Aged 40 years and Older Who Had ASCVD, 
MEPS 2002-2013 
  Odds Ratio (95% CI) 
  Crude (Unadjsuted) Model 1 Model 2 
Cycle       
2002-2003 1 (Reference) 1 (Reference) 1 (Reference) 
2004-2005 2.20 (1.79-2.69) 2.22 (1.81-2.73) 2.15 (1.74-2.65) 
2006-2007 3.15 (2.58-3.86) 3.24 (2.65-3.97) 3.26 (2.66-4.00) 
2008-2009 2.71 (2.22-3.31) 2.78 (2.28-3.41) 2.78 (2.26-3.41) 
2010-2011 2.57 (2.08-3.17) 2.61 (2.12-3.23) 2.33 (1.85-2.93) 
2012-2013 2.00 (1.60-2.50) 2.05 (1.64-2.57) 1.87 (1.50-2.33) 
Age, yrs       
40-64 1 (Reference) 1 (Reference) 1 (Reference) 
65-74 1.19 (1.05-1.35) 1.16 1.02-1.32) 1.03 (0.86-1.25) 
75 & Above 0.75 (0.66-0.86) 0.75 0.66-0.86) 0.71 (0.58-0.87) 
Sex       
Male 1 (Reference) 1 (Reference) 1 (Reference) 
Female 0.67 (0.60-0.75) 0.69 (0.62-0.77) 0.83 (0.74-0.94) 
Race/Ethnicity       
Non-Hispanic White 1 (Reference) 1 (Reference) 1 (Reference) 
Non-Hispanic Black 0.39 (0.32-0.48) 0.39 (0.31-0.48) 0.39 (0.32-0.48) 
Asian 0.80 (0.58-1.10) 0.77 (0.56-1.06) 0.80 (0.56-1.13) 
Hispanic 0.65 (0.54-0.78) 0.63 (0.52-0.76) 0.66 (0.54-0.82) 
Family Income Level (% of FPL)       
Poor (<100%) 1 (Reference) 1 (Reference) 1 (Reference) 
Near Poor (100-124%) 1.15 (0.91-1.45) 1.17 (0.93-1.49) 1.10 (0.88-1.39) 
Low Income (125-199% ) 1.15 (0.97-1.35) 1.16 (0.98-1.38) 1.08 (0.91-1.29) 
Middle Income (200-399%) 1.38 (1.18-1.62) 1.33 (1.13-1.56) 1.18 (1.00-1.40) 
High Income (>=400%) 1.80 (1.55-2.08) 1.62 (1.39-1.88) 1.38 (1.16-1.65) 
Health Insurance       
Uninsured 1 (Reference) 1 (Reference) 1 (Reference) 
Any public (Medicare/Medicaid) 2.19 (1.64-2.92) 2.59 (1.89-3.55) 2.33 (1.68-3.23) 
Private Only 2.77 (2.05-3.75) 2.57 (1.90-3.48) 2.27 (1.63-3.17) 
Education       
<High school 1 (Reference) 1 (Reference) 1 (Reference) 
High school/GED equivalent 1.27 (1.06-1.53) 1.16 (0.96-1.40) 1.06 (0.86-1.30) 
Some college or higher 1.52 (1.26-1.83) 1.32 (1.08-1.60) 1.14 (0.92-1.41) 
Region       
Northeast 1 (Reference) 1 (Reference) 1 (Reference) 
Midwest 1.13 (0.93-1.37) 1.09 (0.90-1.32) 1.12 (0.93-1.37) 
South 0.97 (0.81-1.16) 0.95 (0.79-1.14) 1.02 (0.84-1.23) 
West 0.76 (0.61-0.94) 0.77 (0.62-0.96) 0.79 (0.63-0.98) 
History of CHD 2.37 (2.06-2.74) 2.27 (1.96-2.62) 2.12 (1.74-2.58) 
History of Stroke 0.61 (0.54-0.68) 0.65 (0.58-0.72) 0.97 (0.83-1.14) 
History of PAD  1.68 (1.11-2.54) 1.61 (1.06-2.45) 1.91 (1.28-2.85) 
History of Diabetes  1.84 (1.63-2.07) 1.93 (1.71-2.18) 1.91 (1.69-2.16) 
Statin Use       
No Statin Use 1 (Reference) 1 (Reference) 1 (Reference) 
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Low/Moderate Use 1.09 (0.97-1.23) 1.07 (0.95-1.20) 0.88 (0.76-1.01) 
High Intensity Use 1.94 (1.69-2.23) 1.78 (1.54-2.05) 1.37 (1.18-1.59) 
GCCI*       
0 1 (Reference) 1 (Reference) 1 (Reference) 
1 1.01 (0.88-1.16) 1.05 (0.91-1.21) 0.95 (0.83-1.09) 
>=2 1.03 (0.86-1.22) 1.03 (0.86-1.23) 0.95 (0.79-1.14) 
Abbreviations: CHD, Coronary Heart Disease; FPL, Federal Poverty Level; GCCI, Grouped Charlson 
Comorbidity Index GED, General Education Development; MEPS, Medical Expenditure Panel Survey; PAD, 
Peripheral Arterial Disease 
Model 1: Age, Sex, and Race/ethnicity along with the unvariate predictor of statin use included in the model 
Model 2: All predictor variables were included in this model 
*GCCI was modified for this study by excluding any cardiovascular disease or diabetes from the comorbidity 
index computation 
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 Table S7. Predictors of Nonstatin Use Among U.S. Adults Aged 40 years and Older Who Did Not Have 
ASCVD, MEPS 2002-2013 
  Odds Ratio (95% CI) 
  Crude (Unadjsuted) Model 1 Model 2 
Cycle       
2002-2003 1 (Reference) 1 (Reference) 1 (Reference) 
2004-2005 2.47 (2.12-2.87) 2.48 (2.13-2.88) 2.31 (1.99-2.68) 
2006-2007 3.52 (2.96-4.18) 3.54 (2.98-4.20) 3.27 (2.75-3.89) 
2008-2009 3.52 (2.93-4.22) 3.58 (2.98-4.30) 3.19 (2.66-3.83) 
2010-2011 2.92 (2.44-3.48) 2.96 (2.48-3.52) 2.64 (2.21-3.16) 
2012-2013 2.36 (1.94-2.87) 2.37 (1.95-2.89) 2.10 (1.72-2.54) 
Age, yrs       
40-64 1 (Reference) 1 (Reference) 1 (Reference) 
65-74 2.12 (1.91-2.36) 2.13 (1.91-2.37) 1.12 (0.95-2.54) 
75 & Above 1.71 (1.51-1.94) 1.74 (1.53-1.97) 0.95 (0.79-1.14) 
Sex       
Male 1 (Reference) 1 (Reference) 1 (Reference) 
Female   0.76 (0.67-0.82) 0.79 (0.73-0.85) 
Race/Ethnicity       
Non-Hispanic White 1 (Reference) 1 (Reference) 1 (Reference) 
Non-Hispanic Black 0.45 (0.39-0.53) 0.48 (0.41-0.55) 0.41 (0.35-0.48) 
Hispanic 0.74 (0.66-0.83) 0.78 (0.70-1.42) 0.89 (0.78-1.01) 
Asian 0.75 (0.62-0.90) 0.78 (0.65-0.93) 0.88 (0.73-1.06) 
Family Income Level (% of FPL)       
Poor (<100%) 1 (Reference) 1 (Reference) 1 (Reference) 
Near Poor (100-124%) 0.97 (0.82-1.15) 0.87 (0.73-1.03) 0.88 (0.74-1.06) 
Low Income (125-199% ) 0.90 (0.78-1.03) 0.82 (0.71-0.94) 0.87 (0.75-1.01) 
Middle Income (200-399%) 1.01 (0.89-1.15) 0.97 (0.86-1.11) 1.03 (0.89-1.19) 
High Income (>=400%) 1.11 (0.98-1.27) 1.04 (0.77-1.42) 1.14 (0.97-1.34) 
Health Insurance       
Uninsured 1 (Reference) 1 (Reference) 1 (Reference) 
Any public (Medicare/Medicaid) 4.41 (3.68-5.28) 4.29 (3.53-5.21) 3.05 (2.43-3.83) 
Private Only 2.48 (2.08-2.96) 2.40 (2.01-2.86) 2.14 (1.77-2.59) 
Education       
<High school 1 (Reference) 1 (Reference) 1 (Reference) 
High school/GED equivalent 1.22 (1.05-1.41) 1.26 (1.08-1.47) 1.28 (1.09-1.51) 
Some college or higher 1.10 (0.95-1.26) 1.17 (1.01-1.37) 1.17 (0.99-1.38) 
Region       
Northeast 1 (Reference) 1 (Reference) 1 (Reference) 
Midwest 1.00 (0.85-1.18 0.99 (0.84-1.17) 1.03 (0.87-1.22) 
South 1.23 (1.05-1.43 1.24 (1.07-1.45) 1.35 (1.15-1.58) 
West 0.87 (0.74-1.02 0.90 (0.77-1.06) 0.92 (0.78-1.09) 
History of CHD - - - 
History of Stroke - - - 
History of PAD  - - - 
History of Diabetes  3.77 (3.45-4.12) 3.66 (3.46-4.01) 2.79 2.50-3.12) 
Statin Use       
No Statin Use 1 (Reference) 1 (Reference) 1 (Reference) 
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Low/Moderate Use 2.81 (2.56-3.09) 1.44 (1.28-1.62) 1.85 (1.65-2.07) 
High Intensity Use 5.37 (4.59-6.27) 1.70 (1.43-2.01) 3.24 (2.74-3.84) 
GCCI*       
0 1 (Reference) 1 (Reference) 1 (Reference) 
1 1.44 (1.28-1.61) 2.57 (2.33-2.84) 1.85 (1.65-2.67) 
>=2 1.98 (1.68-2.34) 4.88 (4.16-5.73) 3.24 (2.74-3.84) 
Abbreviations: CHD, Coronary Heart Disease;  FPL, Federal Poverty Level; GCCI, Grouped Charlson 
Comorbidity Index GED, General Education Development; MEPS, Medical Expenditure Panel Survey; PAD, 
Peripheral Arterial Disease 
Model 1: Age, Sex, and Race/ethnicity along with the unvariate predictor of statin use included in the model 
Model 2: All predictor variables were included in this model 
*GCCI was modified for this study by excluding any cardiovascular disease or diabetes from the comorbidity 
index computation 
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Figure S1. Flow Chart Showing the Selection of Study Population.  
 
Abbreviations: BMI, Body Mass Index; MEPS, Medical Expenditure Panel Survey 
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Figure S2. Trends In Utilization of Specific Non-Statin Medication Classes, MEPS 2002-2013. 
           
Abbreviations: ASCVD, atherosclerotic cardiovascular diseases; CAI, Cholesterol Absorption Inhibitors; MEPS, 
Medical Expenditure Panel Survey
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Figure S3. Trends In The Average Expenditure on Non-Statins, MEPS 2002-2013. 
 
 
Abbreviations: ASCVD, atherosclerotic cardiovascular diseases; MEPS, Medical Expenditure Panel Survey 
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